Home > News > APP Announces Positive Results of Intra-Arterial ABI-007
June 4th, 2003
APP Announces Positive Results of Intra-Arterial ABI-007
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014